Effect of liver dysfunction on circulating sclerostin

Yumie Rhee, Won Jin Kim, Ki Jun Han, Sungkil Lim, Se Hwa Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Sclerostin is a Wnt inhibitor produced specifically by osteocytes. It decreases bone formation by repressing osteoblast differentiation and proliferation. Whether circulating sclerostin level is affected by liver function is not currently clear. The aim of the study was to evaluate this relationship. Our cross-sectional study included 47 patients with liver cirrhosis and 50 healthy controls. Serum sclerostin level was analyzed by ELISA. Serum sclerostin levels were significantly higher in patients with cirrhosis than in controls (50.8 ± 38.2 vs. 35.1 ± 8.8 pmol/L, p = 0.008). After further adjustment for age, sex, body mass index, serum creatinine, and presence of diabetes, cirrhosis patients had higher sclerostin than controls. Subgroup analysis found that patients with Child–Pugh class B or C had higher sclerostin levels than patients with class A or controls after adjusting for multiple confounding factors. Multiple regression analysis showed that gender (p = 0.022), presence of diabetes (p < 0.001), albumin (p = 0.010), and serum creatinine (p = 0.037) were independent factors for circulating sclerostin level. Circulating sclerostin was higher in patients with advanced liver cirrhosis than in healthy controls or patients with early liver cirrhosis. The elevated sclerostin levels clearly correlated with markers of liver dysfunction such as albumin. The relationship between circulating sclerostin and liver function indicates a possible role of the liver in sclerostin metabolism.

Original languageEnglish
Pages (from-to)545-549
Number of pages5
JournalJournal of Bone and Mineral Metabolism
Volume32
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Liver Diseases
Liver Cirrhosis
Serum
Albumins
Liver
Creatinine
Fibrosis
Osteocytes
Osteoblasts
Osteogenesis
Body Mass Index
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Cite this

Rhee, Yumie ; Kim, Won Jin ; Han, Ki Jun ; Lim, Sungkil ; Kim, Se Hwa. / Effect of liver dysfunction on circulating sclerostin. In: Journal of Bone and Mineral Metabolism. 2014 ; Vol. 32, No. 5. pp. 545-549.
@article{a7928d22064a4747bb83de00c4203084,
title = "Effect of liver dysfunction on circulating sclerostin",
abstract = "Sclerostin is a Wnt inhibitor produced specifically by osteocytes. It decreases bone formation by repressing osteoblast differentiation and proliferation. Whether circulating sclerostin level is affected by liver function is not currently clear. The aim of the study was to evaluate this relationship. Our cross-sectional study included 47 patients with liver cirrhosis and 50 healthy controls. Serum sclerostin level was analyzed by ELISA. Serum sclerostin levels were significantly higher in patients with cirrhosis than in controls (50.8 ± 38.2 vs. 35.1 ± 8.8 pmol/L, p = 0.008). After further adjustment for age, sex, body mass index, serum creatinine, and presence of diabetes, cirrhosis patients had higher sclerostin than controls. Subgroup analysis found that patients with Child–Pugh class B or C had higher sclerostin levels than patients with class A or controls after adjusting for multiple confounding factors. Multiple regression analysis showed that gender (p = 0.022), presence of diabetes (p < 0.001), albumin (p = 0.010), and serum creatinine (p = 0.037) were independent factors for circulating sclerostin level. Circulating sclerostin was higher in patients with advanced liver cirrhosis than in healthy controls or patients with early liver cirrhosis. The elevated sclerostin levels clearly correlated with markers of liver dysfunction such as albumin. The relationship between circulating sclerostin and liver function indicates a possible role of the liver in sclerostin metabolism.",
author = "Yumie Rhee and Kim, {Won Jin} and Han, {Ki Jun} and Sungkil Lim and Kim, {Se Hwa}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00774-013-0524-z",
language = "English",
volume = "32",
pages = "545--549",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer Japan",
number = "5",

}

Effect of liver dysfunction on circulating sclerostin. / Rhee, Yumie; Kim, Won Jin; Han, Ki Jun; Lim, Sungkil; Kim, Se Hwa.

In: Journal of Bone and Mineral Metabolism, Vol. 32, No. 5, 01.01.2014, p. 545-549.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of liver dysfunction on circulating sclerostin

AU - Rhee, Yumie

AU - Kim, Won Jin

AU - Han, Ki Jun

AU - Lim, Sungkil

AU - Kim, Se Hwa

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Sclerostin is a Wnt inhibitor produced specifically by osteocytes. It decreases bone formation by repressing osteoblast differentiation and proliferation. Whether circulating sclerostin level is affected by liver function is not currently clear. The aim of the study was to evaluate this relationship. Our cross-sectional study included 47 patients with liver cirrhosis and 50 healthy controls. Serum sclerostin level was analyzed by ELISA. Serum sclerostin levels were significantly higher in patients with cirrhosis than in controls (50.8 ± 38.2 vs. 35.1 ± 8.8 pmol/L, p = 0.008). After further adjustment for age, sex, body mass index, serum creatinine, and presence of diabetes, cirrhosis patients had higher sclerostin than controls. Subgroup analysis found that patients with Child–Pugh class B or C had higher sclerostin levels than patients with class A or controls after adjusting for multiple confounding factors. Multiple regression analysis showed that gender (p = 0.022), presence of diabetes (p < 0.001), albumin (p = 0.010), and serum creatinine (p = 0.037) were independent factors for circulating sclerostin level. Circulating sclerostin was higher in patients with advanced liver cirrhosis than in healthy controls or patients with early liver cirrhosis. The elevated sclerostin levels clearly correlated with markers of liver dysfunction such as albumin. The relationship between circulating sclerostin and liver function indicates a possible role of the liver in sclerostin metabolism.

AB - Sclerostin is a Wnt inhibitor produced specifically by osteocytes. It decreases bone formation by repressing osteoblast differentiation and proliferation. Whether circulating sclerostin level is affected by liver function is not currently clear. The aim of the study was to evaluate this relationship. Our cross-sectional study included 47 patients with liver cirrhosis and 50 healthy controls. Serum sclerostin level was analyzed by ELISA. Serum sclerostin levels were significantly higher in patients with cirrhosis than in controls (50.8 ± 38.2 vs. 35.1 ± 8.8 pmol/L, p = 0.008). After further adjustment for age, sex, body mass index, serum creatinine, and presence of diabetes, cirrhosis patients had higher sclerostin than controls. Subgroup analysis found that patients with Child–Pugh class B or C had higher sclerostin levels than patients with class A or controls after adjusting for multiple confounding factors. Multiple regression analysis showed that gender (p = 0.022), presence of diabetes (p < 0.001), albumin (p = 0.010), and serum creatinine (p = 0.037) were independent factors for circulating sclerostin level. Circulating sclerostin was higher in patients with advanced liver cirrhosis than in healthy controls or patients with early liver cirrhosis. The elevated sclerostin levels clearly correlated with markers of liver dysfunction such as albumin. The relationship between circulating sclerostin and liver function indicates a possible role of the liver in sclerostin metabolism.

UR - http://www.scopus.com/inward/record.url?scp=84904203848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904203848&partnerID=8YFLogxK

U2 - 10.1007/s00774-013-0524-z

DO - 10.1007/s00774-013-0524-z

M3 - Article

C2 - 24126695

AN - SCOPUS:84904203848

VL - 32

SP - 545

EP - 549

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

IS - 5

ER -